REFERENZEN 1. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS et al: Cancer im- munology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348(6230):124-128. 9. Pellegatta S, Valletta L, Corbetta C, Patane M, Zucca I, Riccardi Sirtori F, Bruzzone MG, Fogliatto G, Isacchi A, Pollo B et al: Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial gli- oma. Acta Neuropathol Commun 2015, 3:4. 2. Aslan K, Turco V, Blobner J, Sonner JK, Liuzzi AR, Nunez NG, De Feo D, Kickingereder P, Fischer M, Green E et al: Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Nat Commun 2020, 11(1):931. 10. Bunse L, Schumacher T, Sahm F, Pusch S, Oezen I, Rau- schenbach K, Gonzalez M, Solecki G, Osswald M, Capper D et al: Proximity ligation assay evaluates IDH1R132H presentation in gliomas. J Clin Invest 2015, 125(2):593- 606. 3. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS et al: Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014, 344(6184):641-645. 4. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L et al: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017, 547(7662):217-221. 11. Bao R, Stapor D, Luke JJ: Molecular correlates and the- rapeutic targets in T cell-inflamed versus non-T cell-in- flamed tumors across cancer types. Genome Med 2020, 12(1):90. 12. Zhang L, Sorensen MD, Kristensen BW, Reifenberger G, McIntyre TM, Lin F: D-2-Hydroxyglutarate Is an Intercel- lular Mediator in IDH-Mutant Gliomas Inhibiting Com- plement and T Cells. Clin Cancer Res 2018, 24(21):5381- 5391. 5. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M, Bukur V, Tadmor AD, Luxemburger U, Schrors B et al: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Na- ture 2017, 547(7662):222-226. 13. Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K et al: Suppression of antitumor T cell immunity by the on- cometabolite (R)-2-hydroxyglutarate. Nat Med 2018, 24(8):1192-1203. 6. Platten M, Offringa R: Cancer immunotherapy: exploi- ting neoepitopes. Cell Res 2015, 25(8):887-888. 7. Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, Cortes-Ciriano I, Birzu C, Geduldig JE, Pelton K et al: Mechanisms and therapeutic implications of hy- permutation in gliomas. Nature 2020, 580(7804):517- 523. 8. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M et al: A vaccine targeting mutant IDH1 induces antitumour im- munity. Nature 2014, 512(7514):324-327. 14. Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, Chheda ZS, Downey KM, Watchmaker PB, Beppler C et al: Isocitrate dehydrogenase mutations sup- press STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest 2017, 127(4):1425-1437. 15. Bottcher M, Renner K, Berger R, Mentz K, Thomas S, Cardenas-Conejo ZE, Dettmer K, Oefner PJ, Mackensen A, Kreutz M et al: D-2-hydroxyglutarate interferes with HIF-1alpha stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polariza- tion. Oncoimmunology 2018, 7(7):e1445454. 16. Amankulor NM, Kim Y, Arora S, Kargl J, Szulzewsky F, Hanke M, Margineantu DH, Rao A, Bolouri H, Delrow J et al: Mutant IDH1 regulates the tumor-associated immu- ne system in gliomas. Genes Dev 2017, 31(8):774-786. 17. Friebel E, Kapolou K, Unger S, Nunez NG, Utz S, Rushing EJ, Regli L, Weller M, Greter M, Tugues S et al: Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes. Cell 2020, 181(7):1626-1642 e1620. 18. Klemm F, Maas RR, Bowman RL, Kornete M, Soukup K, Nassiri S, Brouland JP, Iacobuzio-Donahue CA, Brennan C, Tabar V et al: Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Al- terations of Immune Cells. Cell 2020, 181(7):1643-1660 e1617. 19. Friedrich M, Sankowski R, Bunse L, Kilian M, Green E, Ramallo Guevara C, Pusch S, Poschet G, Sanghvi K, Hahn M et al: Tryptophan metabolism drives dynamic immu- nosuppressive myeloid states in IDH-mutant gliomas. Nature Cancer 2021. 20. Kadiyala P, Carney SV, Gauss JC, Garcia-Fabiani MB, Haa- se S, Alghamri MS, Nunez FJ, Liu Y, Yu M, Taher A et al: Inhibition of 2-hydroxyglutarate elicits metabolic repro- gramming and mutant IDH1 glioma immunity in mice. J Clin Invest 2021, 131(4). 21. Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I et al: A vaccine targeting mutant IDH1 in newly diagnosed glioma. Na- ture 2021, 592(7854):463-468. 40 AUSGABE 14 . DEZEMBER 2021 . KREBS IM FOCUS